Skip to main content

Table 2 TRAEs occurring in ≥ 10% of patients

From: A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis

 

All patients (n = 52)

Any grade

Grade ≥ 3

Any TRAE

49 (94.2%)

19 (36.5%)

Hypertension

27 (51.9%)

10 (19.2%)

White blood cell count decreased

20 (38.5%)

2 (3.8%)

Neutrophil count decreased

20 (38.5%)

1 (1.9%)

Nausea

16 (30.8%)

0

Asthenia

14 (26.9%)

0

Anaemia

13 (25.0%)

7 (13.5%)

Dizziness

12 (23.1%)

0

Platelet count decreased

10 (19.2%)

3 (5.8%)

Headache

10 (19.2%)

0

Vomiting

10 (19.2%)

0

Diarrhoea

7 (13.5%)

0

Abdominal pain upper

6 (11.5%)

0

Alanine aminotransferase increased

6 (11.5%)

0

Protein urine present

6 (11.5%)

0

  1. Data are n (%). All grade ≥ 3 TRAEs occurring in ≥ 2% of patients are listed. TRAE Treatment-related adverse event